Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.45 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.53 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL6429247 | 1.00 | ALDH1A1 (0.79) | ALDH1A1FFAR3HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL27572377 | 1.00 | ALDH1A1 (0.79) | ALDH1A1FFAR3HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL28058231 | 0.95 | ALDH1A1 (0.71) | ALDH1A1FFAR3HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL28763623 | 0.93 | ALDH1A1 (0.68) | ALDH1A1FFAR3HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL31272367 | 0.92 | ALDH1A1 (0.83) | ALDH1A1FFAR3HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL28224700 | 0.90 | ALDH1A1 (0.71) | ALDH1A1FFAR3HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL31223216 | 0.90 | ALDH1A1 (0.79) | ALDH1A1FFAR3HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL28846450 | 0.90 | ALDH1A1 (0.79) | ALDH1A1FFAR3HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL31223219 | 0.90 | ALDH1A1 (0.79) | ALDH1A1FFAR3HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL226489 | 0.90 | ALDH1A1 (0.79) | ALDH1A1FFAR3HMGCRCHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090148414-A1 | Novel Composition to Improve Gut Health and Animal Performance and Methods of Making the Same | BIOATLANTIS LIMITED (IE) | 2009-06-11 | — | — | US | claimed |
| EP-1126838-A4 | NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2005-02-16 | — | — | EP | claimed |
| US-20030207919-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2003-11-06 | — | — | US | claimed |
| US-6593347-B2 | Especially a nitrosated and/or nitrosylated arylpropionic acid, arylacetic acid, enolic anilide or an oxicam | NITROMED, INC. | 2003-07-15 | — | — | US | claimed |
| JP-2002528495-A | — | — | 2002-09-03 | — | — | JP | claimed |
| US-20020016322-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use | NICOX S.A. (FR) | 2002-02-07 | — | — | US | claimed |
| EP-1126838-A1 | NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2000025776-A1 | NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-05-11 | — | — | WO | claimed |
| CN-109997967-A | Trace element premixing feed acidity regulator and preparation method thereof | 葫芦岛智多多科技有限责任公司 | 2019-07-12 | — | — | CN | disclosed |
| US-RE46377-E1 | Conversion of corn gluten into a solid article | GREEN MATERIALS, LLC (US) | 2017-04-25 | — | — | US | disclosed |
| US-9040597-B2 | Conversion of corn gluten meal into a solid article through the use of a non-toxic additive | GREEN MATERIALS, LLC (US) | 2015-05-26 | — | — | US | disclosed |
| WO-2014093252-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | NEXMED HOLDINGS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20130203881-A1 | CONVERSION OF CORN GLUTEN MEAL INTO A SOLID ARTICLE THROUGH THE USE OF A NON-TOXIC ADDITIVE | GREEN MATERIALS, LLC | 2013-08-08 | — | — | US | disclosed |
| WO-2012012387-A1 | CONVERSION OF CORN GLUTEN MEAL INTO A SOLID ARTICLE THROUGH THE USE OF A NON-TOXIC ADDITIVE | R&D GREEN MATERIALS, LLC (US) | 2012-01-26 | — | — | WO | disclosed |
| US-6593347-B2 | Especially a nitrosated and/or nitrosylated arylpropionic acid, arylacetic acid, enolic anilide or an oxicam | NITROMED, INC. | 2003-07-15 | — | — | US | disclosed |
| US-20020016322-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use | NICOX S.A. (FR) | 2002-02-07 | — | — | US | disclosed |
| EP-1126838-A1 | NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025776-A1 | NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| US-5491050-A | DEVELOPMENT IN PRESENCE OF 1-PHENYLPYRAZOLIDONE-3-ONE | EASTMAN KODAK COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
| US-5290353-A | Vaterite and production method | LHOIST RECHERCHE ET DEVELOPPEMENT S.A. (BE) | 1994-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016322-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use | NOS2, NOS3, NOS1 | MEN1 2276/4885ESR1 2469/4885ESR2 886/4885 |
| US-20030207919-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NOS2, NOS1, NOS3 | MEN1 3390/4885ESR1 2595/4885ESR2 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.